NasdaqGS:LEGNBiotechs
Assessing Legend Biotech (LEGN) Valuation After Oppenheimer Coverage And 2026 Profitability Outlook
Legend Biotech (LEGN) moved higher after Oppenheimer initiated coverage, highlighting Carvykti’s performance compared with other CAR-T therapies and noting profitability expectations for 2026 ahead of the company’s J.P. Morgan Healthcare Conference presentation.
See our latest analysis for Legend Biotech.
At a share price of $23.03, Legend Biotech’s 1-day and 7-day share price returns of 1.36% and 5.93% sit against a 90-day share price return of 27.35% decline and a 1-year total shareholder...